Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Leslie Petch is active.

Publication


Featured researches published by Leslie Petch.


Current Biology | 2000

Integrin engagement suppresses RhoA activity via a c-Src-dependent mechanism

William T. Arthur; Leslie Petch; Keith Burridge

The Rho family GTPases Cdc42, Rac1 and RhoA control many of the changes in the actin cytoskeleton that are triggered when growth factor receptors and integrins bind their ligands [1] [2]. Rac1 and Cdc42 stimulate the formation of protrusive structures such as membrane ruffles, lamellipodia and filopodia. RhoA regulates contractility and assembly of actin stress fibers and focal adhesions. Although prolonged integrin engagement can stimulate RhoA [3] [4] [5], regulation of this GTPase by early integrin-mediated signals is poorly understood. Here we show that integrin engagement initially inactivates RhoA, in a c-Src-dependent manner, but has no effect on Cdc42 or Rac1 activity. Additionally, early integrin signaling induces activation and tyrosine phosphorylation of p190RhoGAP via a mechanism that requires c-Src. Dynamic modulation of RhoA activity appears to have a role in motility, as both inhibition and activation of RhoA hinder migration [6] [7] [8]. Transient suppression of RhoA by integrins may alleviate contractile forces that would otherwise impede protrusion at the leading edge of migrating cells.


Current Biology | 2000

The protein tyrosine phosphatase Shp-2 regulates RhoA activity

Simone M. Schoenwaelder; Leslie Petch; David Williamson; Randy Shen; Gen-Sheng Feng; Keith Burridge

Remodeling of filamentous actin into distinct arrangements is precisely controlled by members of the Rho family of small GTPases [1]. A well characterized member of this family is RhoA, whose activation results in reorganization of the cytoskeleton into thick actin stress fibers terminating in integrin-rich focal adhesions [2]. Regulation of RhoA is required to maintain adhesion in stationary cells, but is also critical for cell spreading and migration [3]. Despite its biological importance, the signaling events leading to RhoA activation are not fully understood. Several independent studies have implicated tyrosine phosphorylation as a critical event upstream of RhoA [4]. Consistent with this, our recent studies have demonstrated the existence of a protein tyrosine phosphatase (PTPase), sensitive to the dipeptide aldehyde calpeptin, acting upstream of RhoA [5]. Here we identify the SH2 (Src homology region 2)-containing PTPase Shp-2 as a calpeptin-sensitive PTPase, and show that calpeptin interferes with the catalytic activity of Shp-2 in vitro and with Shp-2 signaling in vivo. Finally, we show that perturbation of Shp-2 activity by a variety of genetic manipulations results in raised levels of active RhoA. Together, these studies identify Shp-2 as a PTPase acting upstream of RhoA to regulate its activity and contribute to the coordinated control of cell movement.


Cell Adhesion and Communication | 1997

E-Cadherin Engagement Stimulates Tyrosine Phosphorylation

Michael S. Kinch; Leslie Petch; Cuiling Zhong; Keith Burridge

Cadherins are cell adhesion molecules concentrated at intercellular adherens junctions, where they form a multiprotein complex with cytoplasmic catenins. Although cell-cell interactions affect many aspects of cell behavior, little is known about signaling pathways triggered by cadherin engagement. We show here that E-cadherin-mediated cell-cell adhesion leads to a rapid increase in tyrosine phosphorylation at sites of cell-cell contact and that this stimulation of tyrosine phosphorylation can be mimicked by aggregation of E-cadherin with antibodies. The proteins that become phosphorylated are distinct from those previously shown to be tyrosine phosphorylated in response to integrin-mediated adhesion and include ras-GAP. We also find that E-cadherin-mediated tyrosine phosphorylation is not required for the assembly of adherens-type junctions.


Journal of Acquired Immune Deficiency Syndromes | 2004

Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women.

Sherene S. Min; Amanda H. Corbett; Naser L. Rezk; Susan Cu-Uvin; Susan A. Fiscus; Leslie Petch; Myron S. Cohen; Angela D. M. Kashuba

The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.


The Journal of Infectious Diseases | 2002

Pharmacokinetic and Pharmacodynamic Investigation of Efavirenz in the Semen and Blood of Human Immunodeficiency Virus Type 1–Infected Men

Y. Sunila Reddy; S. Karl Gotzkowsky; Joseph J. Eron; Julie Y. Kim; William Fiske; Susan A. Fiscus; Leslie Petch; Myron S. Cohen; Angela D. M. Kashuba

Therapeutic concentrations of antiretroviral agents in seminal plasma (SP) may reduce virus burden and influence sexual transmission of human immunodeficiency virus (HIV) type 1. This study compared the pharmacokinetic, pharmacodynamic, and dose responses of efavirenz (EFV) in SP versus those in blood plasma (BP). A total of 431 BP samples and 157 SP samples were obtained over a period of 40 days, from 9 EFV-naive men (i.e., men about to receive EFV for the first time) and from 12 EFV-experienced men (i.e., men already receiving EFV as part of an antiretroviral regimen). Overall, median EFV exposure in SP was 3.4% (range, 2.0%-5.0%) of that in BP. However, all EFV concentrations in SP were >/=40-fold higher than the wild-type IC(90) (IC(90)(WT)) for HIV-1. During the dosing interval, no single SPrcolon;BP EFV-concentration ratio was significantly predictive of the absolute measure of exposure in SP. By day 40, HIV-1 RNA in SP was undetectable in 8 (89%) of 9 EFV-naive men and remained undetectable in 10 (83%) of 12 EFV-experienced men. In SP, EFV reaches concentrations above the HIV-1 IC(90)(WT) throughout the dosing interval. EFV-containing regimens effectively suppress HIV-1 RNA in SP.


AIDS Research and Human Retroviruses | 2008

Genotypic Susceptibility Scores and HIV Type 1 RNA Responses in Treatment-Experienced Subjects with HIV Type 1 Infection

Jeffrey A. Anderson; Hongyu Jiang; Xiao Ding; Leslie Petch; Terri Journigan; Susan A. Fiscus; Richard Haubrich; David Katzenstein; Ronald Swanstrom; Roy M. Gulick

This study compared the role of genotypic susceptibility scores (GSS) as a predictor of virologic response in a group (n = 234) of HIV-infected, protease inhibitor (PI)-experienced subjects. Two scoring methods [discrete genotypic susceptibility score (dGSS) and continuous genotypic susceptibility score (cGSS)] were developed. Each drug in the subjects regimen was given a binary susceptibility score using Stanford inferred drug resistance scores to calculate the dGSS. In contrast to the dGSS, the cGSS model was designed to reflect partial susceptibility to a drug. Both GSS were independent predictors of week 16 virologic response. We also compared the GSS to a phenotypic susceptibility score (PSS) model on a subset of subjects that had both GSS and PSS performed, and found that both models were predictive of virologic response. Genotypic analyses at enrollment showed that subjects who were virologic nonresponders at week 16 revealed enrichment of several mutated codons associated with nucleoside reverse transcriptase inhibitors (NRTI) (codons 67, 69, 70, 118, 215, and 219) or PI resistance (codons 10, 24, 71, 73, and 88) compared to subjects who were virologic responders. Regression analyses revealed that protease mutations at codons 24 and 90 were most predictive of poor virologic response, whereas mutations at 82 were associated with enhanced virologic response. Certain NNRTI-associated mutations, such as K103N, were rapidly selected in the absence of NRTIs. These data indicate that GSS may be a useful tool in selecting drug regimens in HIV-1-infected subjects to maximize virologic response and improve treatment outcomes.


Hiv Clinical Trials | 2007

Non-Nucleoside Phenotypic Hypersusceptibility Cut-Point Determination from ACTG 359

Richard Haubrich; Hongyu Jiang; Ronald Swanstrom; Michael Bates; David Katzenstein; Leslie Petch; Courtney V. Fletcher; Susan A. Fiscus; Roy M. Gulick

Abstract Purpose: Non–nucleoside reverse transcriptase inhibitor (NNRTI) hypersusceptibility (HS) improves virologic response to those agents, but phenotypic susceptibility cut–points, and methods to determine the cut-points, have not been completely defined. Method: Phenotypic drug susceptibility (fold change in IC50 [FC]) was determined for 96 randomly selected antiretroviral–experienced, NNRTI–naive patients who received a delavirdine (DLV)–containing regimen in ACTG 359. A weighted FC score was used to account for other regimen agents. Regression models were used to define baseline DLV HS cut-points using week 4 or week 16 responses. Results: At study entry, DLV HS was present in 36% (35/96) of patients. Models explored HS cut-points from 0.2–1.0 using the week 4 virologic response. Using either a binary or continuous endpoint, DLV HS cut-points between 0.3 and 0.4 were identified. The classification and regression tree (CART) analysis identified baseline DLV FC <0.44 as a predictor of week 4 response. Conclusions: In relating drug HS to virologic response, several different analytic methods identified a DLV HS FC cut–point of 0.3–0.4. In refining phenotypic cut-points, early virologic responses (not confounded by rebound) may be better metrics than later responses, especially for drugs with low genetic barriers, such as DLV.


Aids Research and Therapy | 2007

Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338)

Susan A. Fiscus; Andrea Kovacs; Leslie Petch; Chengcheng Hu; Andrew Wiznia; Lynne M. Mofenson; Ram Yogev; Kenneth McIntosh; Stephen I. Pelton; Sonia Napravnik; Kenneth Stanley; Sharon Nachman

BackgroundThe association between baseline drug resistance mutations and subsequent increase in viral failure has not been established for HIV-infected children. We evaluated drug resistance mutations at 39 codon sites (21 protease inhibitor (PI) resistant codons and 18 nucleoside reverse transcriptase inhibitor (NRTI) resistant codons) for 92 clinically stable NRTI-experienced, PI-naive HIV-infected children 2 to 17 years of age who were initiating new therapy with ritonavir plus zidovudine (ZDV) and lamivudine or plus stavudine. The association between baseline drug resistance mutations and subsequent viral failure after 12 and 24 weeks of highly active antiretroviral therapy (HAART) was studied.ResultsThere were few primary PI associated mutations in this PI-naïve population, but 84% had NRTI mutations – codons 215 (66%), 41 (42%), 67 (37%), 210 (33%) and 70 (32%). None of the specific baseline drug resistance mutations were associated with a higher rate of virologic failure after 12 or 24 weeks of HAART. Median week 12 viral load decreased as the total number of NRTI mutations at baseline increased (P = 0.006). Specifically, a higher level of baseline ZDV resistance mutation was associated with a decrease in viral failure after 12 weeks on a ZDV-containing HAART regimen (P = 0.017).ConclusionNo increase was seen in the rate of viral failure after HAART associated with the presence of resistance mutations at baseline. This paradoxical result may be due to adherence, replicative capacity, or ZDV hypersusceptibility to the new regimen.


Archive | 1991

The Epidermal Growth Factor Receptor: Control of Synthesis and Signaling Function

Shelton Earp; William R. Huckle; Vw Raymond; Leslie Petch; Sherry Marts; Warren Bishop; Bryan McCune

This chapter serves two functions. The first is to introduce the area of growth factor receptors and signal transduction to an audience well versed in the action of reproductive tract hormones. The second is to summarize work from our own lab regarding the regulation of synthesis and function of the rat epidermal growth factor (EGF) receptor.


Molecular and Cellular Biology | 1990

A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue.

Leslie Petch; J. A. Harris; Vw Raymond; A Blasband; Daekee Lee; H. S. Earp

Collaboration


Dive into the Leslie Petch's collaboration.

Top Co-Authors

Avatar

Susan A. Fiscus

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Keith Burridge

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Myron S. Cohen

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

T K Harden

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Vw Raymond

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Angela D. M. Kashuba

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Bryan McCune

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

H. S. Earp

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge